Origin Sciences Secures North American Distributor

Press Release: Origin Sciences Secures North American Distributor

01 June 2016 — London and Cambridge, UK —

Origin Sciences Ltd, a medical technology company developing unique sampling devices and diagnostics for the stratification of patients with gastrointestinal diseases, has secured Metabiomics as a distributor for The United States of America.

Metabiomics is a US based, early stage molecular diagnostics company that is developing in-vitro diagnostics, screening tests, and health assays that leverage breakthroughs in next-generation DNA sequencing, computational systems biology, and human microbiome sciences.

The distribution agreement will see Metabiomics sell Origin’s products in North America for research into gastrointestinal diseases. These products include Oricol, an effective, CE marked tool for sampling the rectal mucosa for investigating gastrointestinal disease, and the Oricol Microbiome Sampling Kit, which has been specifically designed for use in gut microbiome research, a fast-growing area of the life sciences industry.

Paul Weinberger, CEO of Origin Sciences said: “The North American market is one of the largest and fastest growing markets for both diagnostic and research kits for gastrointestinal disease. We are extremely pleased to have concluded this agreement, as expansion into North America is a key part of the commercialisation strategy for Origin. This follows a very successful year for Origin which as well as seeing increased uptake of the Oricol device, saw the launch of our Microbiome Sampling Kit.

Metabiomics President and COO, Greg Kuehn, added "Metabiomics is excited to offer the Oricol microbiome sampling kit for the development of new microbiome diagnostics and other applications. Oricol delivers a highly enriched and representative sample of the mucosa which may be an important advance over current stool sample and rectal swab methods used for studying the gut microbiome."

Since 2014 Origin has made significant progress in developing and commercialising its diagnostic technology. 2014 saw the launch of Oricol, a sampling device for investigating gastrointestinal disease, while 2015 has seen the company expand its commercial presence to South East Asia and the US, and launch its Microbiome Research Kit. In addition, the company has been active in expanding its scientific research and has published data showing the benefits of using Oricol compared to traditional methods for research into the gut microbiome.

ENDS